Leukeran Case Study

1577 Words7 Pages
As the Tisagenlecleucel consists of whole cells which are not absorbed by the body, route of passage through gastrointestinal tract is difficult because of its larger size so it is administered intravenously and enter the blood stream. Intravenous drug administration is the best option as it is convenient for both the patient and blood is the intended target location for the drug as most of the leukemic cells are in the blood. Tisagenlecleucel is administered once [9]. Leukeran is administered orally in the form of a tablet. The usual dosage and frequency of leukeran is 0.1-0.2mg/kg*day for 3-6 weeks. It needs periodic blood controls to see if the WBC cells decrease excessively to check if there is any necessity to reduce the dosage or to stop the treatment permanently [10].…show more content…
This time is enough for the reengineered cells to grow, divide and attack their targets and the remission stage for the patients was observed within 30 days after infusion indicating that one dose would be enough [2] whereas the half-life of leukeran on average at usual dose is about 1.5 hours [3]. The metabolism for Tisagenlecleucel is not applicable (as the cells die due to limited life span of T-cells) and the elimination is through normal pathways to eliminate dead cells [2]. Leukeran is metabolised in the liver to phenylacetic acid mustard which possess antineoplastic function. Both are degraded to monohydroxy and dihydroxy derivatives and excreted out as bile

More about Leukeran Case Study

Open Document